Assenagon Asset Management S.A. Dyne Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	SELL	$6.62 - $13.64 $2.88 Million - $5.93 Million	-434,830 Reduced 60.27%	286,644 $3.81 Million
Q3 2023 Nov 06, 2023	BUY	$8.6 - $12.18 $1.22 Million - $1.73 Million	142,083 Added 24.52%	721,474 $6.46 Million
Q2 2023 Jul 25, 2023	BUY	$8.53 - $14.28 $4,606 - $7,711	540 Added 0.09%	579,391 $6.52 Million
Q1 2023 Apr 18, 2023	BUY	$10.88 - $15.0 $3.44 Million - $4.74 Million	315,825 Added 120.07%	578,851 $6.67 Million
Q3 2022 Oct 27, 2022	SELL	$7.2 - $15.17 $25,819 - $54,399	-3,586 Reduced 1.35%	263,026 $3.34 Million
Q2 2022 Jul 27, 2022	SELL	$4.36 - $10.5 $124,770 - $300,478	-28,617 Reduced 9.69%	266,612 $1.83 Million
Q1 2022 Apr 25, 2022	SELL	$6.52 - $12.27 $434,910 - $818,458	-66,704 Reduced 18.43%	295,229 $2.85 Million
Q4 2021 Feb 01, 2022	BUY	$11.89 - $16.07 $4.3 Million - $5.82 Million	361,933 New	361,933 $4.3 Million

209

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.22B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.